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Abstract: Osteoarthritis (OA) is a physically and emotionally debilitating disease that 
predominantly affects the aging adult population. Current pharmacologic treatment options 
primarily consist of nonsteroidal anti-inflammatory drugs and/or acetaminophen, but associated 
side effects, analgesic limitations, especially in the elderly, and the need for around-the-clock 
analgesia have led physicians to search for alternative analgesics. Opioids have shown 
effectiveness at mitigating both chronic cancer and noncancer pain, and their ability to be 
placed into controlled release (CR) formulations suggests that they may prove efficacious for 
OA patients. One formulation, oxycodone CR, has shown effectiveness in cancer pain patients 
and in some trials of noncancer low back pain. In this review, the objective was to synthesize 
the reported findings by researchers in this field and present an up-to-date look at the efficacy, 
safety, and tolerability of oxycodone CR in OA patients. Public literature databases were searched 
using specific keywords (eg, oxycodone CR) for studies assessing the efficacy and safety profile 
of oxycodone CR and its use in patients with OA. A total of eleven articles that matched the 
criteria were identified, which included three placebo-controlled trials, six comparative trials, 
one pharmacokinetic study in the elderly, and one long-term safety trial. Analysis of the studies 
revealed that oxycodone CR is reasonably efficacious, safe, and tolerable when used to manage 
moderate to severe chronic OA pain, with similar side effects to that of other opioids.
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Introduction
Osteoarthritis is a common joint disorder among the older adult population.1,2 One 
in four adults over the age of 65 worldwide are affected by this disease,3 and the 
prevalence has been reported to be 27.2%, 13.8%, and 27.0% in hands, knees, and hips, 
respectively.4,5 It is a disease that ultimately leads to destruction of the cartilage and 
the bone in the joints,6 and can be a result of a number of factors besides age including 
genetics, gender, race, weight, and diet.7 Severe chronic pain is known to be associated 
with the disease and contributes substantially to a patient’s disability,8 in addition to 
having a negative impact on motor function, sleep, mood, and overall quality of life.9 
Thus, a major goal of therapy has been for the control of pain.10
Osteoarthritis is comprised of a complex collection of pathophysiological processes 
that both individually and in combination give rise to a multifaceted variety of pain types. 
It includes damage and degradation of several joint structures and tissue types, such as 
cartilage (reduced proteoglycan content), smooth muscle, and bone. In   addition, new 
bone outgrowths at the margins of the injury further irritate the surrounding areas (eg, a 
joint capsule) and recruit a cascade of more inflammatory responses. The multifactorial 
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combination of mechanical and biochemical insults together 
with inflammation lead to a pain of multifaceted etiology 
and type. Treatment of such a complex pain is unlikely to 
be successful using an analgesic regimen that relies only on 
one analgesic class approach. Thus, opioids, both from a 
mechanistic and efficacy point of view, with adequate precau-
tions are a rational pharmacologic option for the appropriate 
patient and situation.
Current treatment options for reducing pain com-
bine pharmacologic and nonpharmacologic approaches. 
Nonpharmacologic approaches may consist of physical 
and occupational therapy in addition to increasing patient 
awareness and education.11 Pharmacologic approaches usu-
ally consist of analgesic therapy. Initial analgesic therapy 
may consist of acetaminophen, salicylates, nonsteroidal 
anti-inflammatory drugs, or weak opioids (eg, propoxy-
phene) and mixed-acting analgesics (eg, tramadol).11–14 Use 
of these analgesics, especially acetaminophen and nonsteroi-
dal anti-inflammatory drugs, have limitations and have been 
shown to be mildly effective to noneffective in some stud-
ies.15–18 Some of these limitations include an analgesic ceiling 
effect and any increase of dosage can lead to a number of side 
effects including hepatotoxicity, renal toxicity, cardiovascular 
effects, and gastrointestinal effects.19–25
Such limitations have led some physicians to exam-
ine alternative analgesics for osteoarthritis. Opioids have 
demonstrated their effectiveness in mitigating pain related 
to both chronic cancer and noncancer pain and thus have 
recently been viewed as a viable alternative. Several reviews 
summarize the appropriateness, efficacy, and safety of opioid 
use for treatment of the pain associated with osteoarthritis. 
For example, McHughes and Lipman discuss opioids as an 
option for OA pain when other interventions are insufficient26 
and Howes et al included a Cochrane systematic review of 
studies that involved trials in which patients received placebo 
or oral codeine, morphine, oxycodone, or oxymorphone.27 
Both reviews concluded that the evidence from such trials 
supports the use of opioids as part of a comprehensive 
approach in the management of osteoarthritis pain.
Immediate release forms of various opioids have demon-
strated efficacy and safety for use for some chronic pain con-
ditions;28 however, it has been recommended that for chronic 
continuous pain, opioids should be administered around-the-
clock in order to provide consistent pain relief.29 This can pose 
a challenge for the use of immediate release formulations as 
this requires a patient to frequently administer their medication 
in order to prevent any breaks in pain relief. To circumvent 
this problem and other problems associated with immediate 
release formulations, extended release (ER)/controlled release 
(CR) formulations of some opioids have been marketed. 
Advantages of ER opioids may include:
•	 Provides sustained analgesia for 12–24 hours, thus no 
gaps in pain relief;30,31
•	 Provides consistent plasma concentrations;32
•	 Eliminates need to wait for pain to return before taking 
next dose;33
•	 May help with better nighttime pain control;33
•	 May help increase compliance;
•	 Less “clock-watching”
Several oral analgesics are available in ER formulations 
and these include oxymorphone ER, oxycodone CR, morphine 
ER, tramadol ER, fentanyl transdermal, and buprenor-
phine transdermal. Oxycodone CR is a twice-daily (every 
12 hours) formulation that has been reported to be effective 
in the management of cancer pain34–38 and chronic noncan-
cer pain.39,40 Its use in osteoarthritis has been tested in both 
placebo-controlled and comparative studies, and a summary 
and evaluation of those studies is the focus of this review.
Because the management of pain for patients who have 
moderate to severe chronic pain related to osteoarthritis 
requires around-the-clock analgesia, it is reasonable to pos-
tulate that ER or CR formulations might provide patients 
with not only a simpler dosing schedule, but also a more 
consistent and enduring relief from pain. It was the objective 
of this review to evaluate this for an opioid that had sufficient 
available literature. Oxycodone CR formulation provided 
such an opportunity.
Methods
Literature search strategy
The strategy for the identification of studies included the 
electronic searching of the PubMed/MEDLINE database, 
EMBASE, and The Cochrane Library from database incep-
tion to December 2011. Search terms that were used included: 
“osteoarthritis,” “oxycodone,” “CR” [controlled release], 
“ER” [extended release]. Terms were selected based on the 
main terms in the title of the review. Terms were not used 
individually, but in combination in order to achieve a highly 
condensed and focused result list. Combinations included: 
“osteoarthritis AND oxycodone,” “osteoarthritis AND oxy-
codone AND CR,” “o  steoarthritis AND oxycodone AND 
ER,” “oxycodone AND CR,” “oxycodone AND ER.”
Selection criteria
The identified citations were then further limited to any 
clinical study or review article describing the safety, efficacy, 
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and/or tolerability of oxycodone CR for osteoarthritis. Studies 
that analyzed other chronic pain conditions in conjugation 
with osteoarthritis were also included. Studies exclusively 
describing only immediate release forms of oxycodone were 
not included. The initial literature search was performed by 
author RT and all articles were analyzed by all of the authors. 
To identify potential articles missed by the electronic search, 
the bibliographies of the electronically identified articles were 
analyzed and any appropriate article based on the title and 
abstract were retrieved.
Assessment of methodological quality
The quality of the articles extracted was not assessed. The 
goal was to present published studies regardless of the design 
type and quality. The intention was to present to the reader 
all research conducted on the current topic.
Data extraction and analysis
Data extracted from the studies included pain intensities, 
quality of life assessments, and adverse events (AEs). No 
formal statistical or meta-analysis was conducted on the 
studies and this task was beyond the scope of this review.
Results
Literature search
In the literature search, a total of eleven articles were identi-
fied that reviewed the safety, efficacy, and/or tolerability of 
oxycodone CR and its use in patients with osteoarthritis. 
All eleven studies were reviewed and included in this 
review. The studies included three placebo-controlled trials, 
six comparative trials, one pharmacokinetic study in the 
elderly, and one long-term safety trial. The comparative 
studies looked at oxycodone versus either oxymorphone, 
hydromorphone, or tapentadol.
Placebo-controlled trials  
of CR formulation of oxycodone
Pain intensity
In a trial of 167 patients with moderate to severe chronic 
osteoarthritis pain, oxycodone CR formulation was 
compared to placebo for up to 30 days.41 After a titra-
tion period using immediate release oxycodone, patients’ 
pain intensity decreased from 2.44 to 1.48 (P = 0.0001) 
on a four-point scale and was significantly superior to the 
placebo (P # 0.05). In another trial of 133 patients using 
oxycodone CR (OxyContin®), daily mean pain intensity 
was significantly (P , 0.05) reduced at week one and week 
two assessment with 20 mg every 12 hours taken every day 
when compared to placebo. There was no difference in pain 
intensity throughout the day and evening, indicating a stable, 
continuous relief from pain. In addition, a 20% reduction 
in pain was achieved within 1 day of taking 20 mg every 
12 hours and 2 days of taking 10 mg every 12 hours.42 When 
the trial was extended up to 72 weeks, pain intensity remained 
below a moderate level (less than two on a four-point scale) 
throughout the study. In another study conducted by Marken-
son et al using oxycodone CR (OxyContin) average pain 
intensity as measured by a ten-point Brief Pain Inventory 
scale was significantly reduced in the oxycodone group 
versus placebo (5.1 versus 6.0; P = 0.022) at visit two and 
(4.9 versus 6.0; P = 0.024) at 90 days, with approximately 
38% of the patients achieving a 30% reduction in pain at the 
end of 90 days.43 Other Brief Pain Inventory assessments for 
pain including pain “right now,” “worst pain,” “least pain,” 
and “pain relief” were all improved from baseline values and 
were significantly superior to placebo. In addition, Western 
Ontario and McMaster University Osteoarthritis Index scores 
at 30 and 60 days of treatment were significantly reduced 
for pain (−13.0 and −17.8 versus −4.1 and −2.4), stiffness 
(−15.8 and −21.7 versus 0.3 and 0.1), and physical function 
(−12.4 and −17.1 versus −3.2 and −3.8) in patients taking 
oxycodone CR versus placebo, respectively.43 Overall, pain 
intensity was significantly reduced in the oxycodone CR 
group versus placebo in all three trials indicating oxycodone 
CR’s effectiveness in mitigating pain in osteoarthritis.
Quality of life assessments
In a study by Caldwell et al, sleep quality was compared in 
patients receiving oxycodone CR versus placebo.41 Sleep 
scores improved from 2.58 to 3.57 on a five-point scale 
(P = 0.0001) and was significantly superior to placebo 
(P # 0.05). In a trial of 133 patients, use of 20 mg every 
12 hours oxycodone CR for up to 2 weeks significantly 
improved a patient’s mood, sleep, and enjoyment of life, in 
addition to improving the patients’ walking ability, general 
activity, normal work, and their relations with others. Daily 
activities were able to be performed with minimal to no 
difficulty and the patients’ performance were not impaired 
due to oxycodone CR.42 When the trial was extended up to 
72 weeks, daily activities were unaffected to moderately 
affected by pain and their sleep was considered “fair to good,” 
with the number of awakenings reduced by approximately 
50% after 6 months (1.7 versus 0.7). In addition, the patients’ 
performance on daily activities did not decline with chronic 
use of oxycodone CR. In the study conducted by Markenson 
et al, oxycodone CR significantly reduced interference 
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caused by pain with various daily activities including general 
activity, mood, normal work, sleep, walking ability, and 
enjoyment of life.43 The group also assessed pain during a 
patient’s primary activity by using the Patient Generated 
Index, which is a tool to assess a patient’s satisfaction with 
activities selected by the patient as important to improve. 
The scores were significantly higher for patients on oxy-
codone CR versus placebo at days 30 and 45 (P = 0.027 
and P = 0.007, respectively) indicating an improvement in 
the patients’ activities. Overall, patients were satisfied with 
oxycodone CR.43 Overall, patients receiving oxycodone CR 
experienced a significant improvement in various quality of 
life parameters including mood, sleep, enjoyment of life, 
and physical activity.
AEs
AEs associated with oxycodone CR in Caldwell et al’s 
study were those generally seen with opioids. In addition, 
the effects of nausea and dry mouth were of lower incidence 
when compared to patients on immediate release   oxycodone.41 
In a trial of 133 patients, 87 (65.4%) of 133 patients reported 
at least one treatment-emergent AE during the study; the most 
common were known opioid-related side effects. A total of 
70 patients (52.6%) discontinued study participation prema-
turely, 39 because of ineffective treatment (significantly more 
in the placebo group, P , 0.001 for 20 mg every 12 hours) 
and 28 because of AEs (predominantly nausea, vomiting, 
and somnolence in active groups). In the long-term exten-
sion, more than 10% of the population experienced AEs that 
were related to opioids (constipation, somnolence, nausea, 
pruritus, nervousness, headache, and insomnia, with five 
patients experiencing probable drug-related serious AEs 
that resulted in hospitalization.42 In the study conducted by 
Markenson et al, AEs experienced were those typical of an 
oral opioid analgesic with a total of 28 (55%) patients in the 
placebo group and 52 (93%) of patients in the oxycodone CR 
group reporting AEs. Three serious AEs were experienced in 
the oxycodone group with 36% of the patients discontinued 
due to AEs.43 Overall, AEs experienced by patients in the 
placebo-controlled trials resembled that of other opioids, 
which included nausea, vomiting, somnolence, dry mouth, 
and constipation.
Recently a group led by Saari et al examined the age 
effects on the pharmacokinetics of oxycodone.44 The elimi-
nation half-life of intravenous oxycodone showed an age-
dependent increase from 3.8 hours to 4.6 hours in patients 
between the age of 25 years and 85 years, respectively, and 
simulations of repetitive bolus dosing showed a 20% increase 
in oxycodone concentration in the elderly. The review did 
not include a measure of AEs, so the clinical implications of 
the pharmacokinetic changes are not known, but the study 
authors suggested that dosing should be reduced and carefully 
titrated in the elderly in order to avoid excess accumulation 
of oxycodone and potentially hazardous side effects.
Comparative trials
Oxymorphone ER versus oxycodone CR
In a trial of 491 patients, two doses of oxymorphone ER were 
compared to oxycodone CR and placebo for up to 4 weeks.45 
Mean pain intensity at study visits from baseline to 3 weeks 
significantly decreased in the oxymorphone groups (20 mg 
every 12 hours or 40 mg every 12 hours) while the oxycodone 
CR (20 mg every 12 hours) trended toward significance. 
A similar assessment was made when patient diaries were 
analyzed for pain. Changes in Western Ontario and McMaster 
University Osteoarthritis Index scores for pain, stiffness, 
and physical function were statistically improved from 
baseline to week four in the oxymorphone ER groups, but 
were not for the oxycodone CR group. A total of 110 (91%) 
in the oxymorphone ER 40 mg group, 113 (95%) in the 
oxymorphone ER 20 mg group, 110 (88%) in the oxycodone 
CR 20 mg group, and 71 (57%) in the placebo group 
experienced AEs that were considered mild to moderate 
and were those typically observed with opioid treatment. 
There was a clinically meaningful greater incidence of 
nausea (60%–61% versus 43%), vomiting (23%–34% 
versus 10%), and pruritus (19%–25% versus 8%), and a 
clinically meaningful lower incidence of headache (6%–11% 
versus 18%) in the groups taking oxymorphone ER compared 
with the group taking oxycodone CR. Overall, oxymorphone 
ER proved to be superior compared to oxycodone CR in 
regard to pain intensity reduction and the occurrence of 
side effects.
Hydromorphone ER versus  
oxycodone CR
Hale et al analyzed the safety and efficacy of once-a-day 
hydromorphone ER (N = 71) to oxycodone CR (OxyContin) 
(N = 67) for up to 6 weeks for patients with moderate to 
severe osteoarthritic pain.46 Mean change in pain intensity 
on a four-point scale from baseline to end point was similar 
between hydromorphone and oxycodone (−0.6 versus −0.4, 
95% confidence interval −0.53 to ∞). In addition, patient 
global evaluations and their rating on overall effectiveness 
of treatment were similar. Treatment-emergent AEs occurred 
in 78.9% (56/71) of patients in the hydromorphone group 
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and 79.1% (53/67) of patients in the oxycodone CR group 
with similar rates of discontinuation in both groups. Other 
studies have also shown improvement in different sleep out-
comes and on the Western Ontario and McMaster University 
Osteoarthritis Index scale for pain, stiffness, and physical 
function for both hydromorphone and oxycodone CR.47 
Overall, both hydromorphone ER and oxycodone CR are 
adequate for providing pain relief and have a similar risk/
benefit ratio.
Tapentadol ER versus oxycodone CR
In a study by Afilalo et al, safety and efficacy of ER t  apentadol 
was compared to placebo and oxycodone CR (OxyContin) for 
up to 12 weeks in 1023 patients.48 Patients were titrated for 
3 weeks and then maintained for up to 12 weeks. Tapentadol 
ER significantly reduced average pain intensity from baseline 
to week twelve, whereas oxycodone CR did not. Both drugs, 
however, significantly reduced pain intensity through the 
12-week maintenance period. A greater number of patients 
achieved .50% improvement in pain intensity in the tapent-
adol ER group (32.0% [110/344]) than in the oxycodone CR 
group (17.3% [59/342]; P = 0.023 versus placebo). Patients 
in the tapentadol ER and oxycodone CR groups, respectively, 
experienced at least one treatment-emergent AE (75.9% 
[261/344] versus 87.4% [299/342]). Incidences of constipa-
tion, nausea, vomiting, pruritus, and somnolence were signifi-
cantly lower in the tapentadol group versus oxycodone.
In another study, the long-term safety and efficacy of 
oxycodone CR was compared to an ER formulation of 
tapentadol in patients with chronic pain associated with 
osteoarthritis of the hip and knee.49 A total of 894 patients 
received tapentadol and 223 patients received oxycodone 
CR for up to 1 year. Overall, 85.7% (766/894) of patients in 
the tapentadol ER group and 90.6% (202/223) of patients in 
the oxycodone CR group experienced at least one treatment-
emergent AE. The most common treatment-emergent AEs 
included constipation (38.6% oxycodone versus 22.6% 
tapentadol), nausea (33.2% oxycodone versus 18.1% tapent-
adol), dizziness (19.3% versus 14.8%), somnolence, vomiting 
(13.5% versus 7%), headache, fatigue, and pruritus (10.3% 
versus 5.4%).   Serious treatment-emergent AEs were low with 
4.0% in the oxycodone group versus 5.5% in the tapentadol 
group. Pain intensity scores changed from 7.6 to 4.4 in the 
tapentadol ER group and 7.6 to 4.5 in the oxycodone CR 
groups from the start of study to final endpoint. For both 
tapentadol ER and oxycodone CR, respectively, ratings on 
the global assessment of study medication of “excellent,” 
“very good,” or “good” were reported by the majority of 
patients (75.1% [616/820] and 72.3% [128/177]) and inves-
tigators (77.3% [635/821] and 72.3% [128/177]) at the end 
of treatment.
Both tapentadol and oxycodone were effective at reducing 
pain intensity in both studies, but tapentadol presented a 
better benefit/risk profile. This conclusion was also made 
after a pooled analysis of three phase III studies comparing 
tapentadol ER to oxycodone CR in patients with osteoarthritis 
and chronic low back pain.50
Overall, oxycodone CR was not superior in effectiveness 
or safety when compared to oxymorphone, hydromorphone, 
or tapentadol (Table 1). Pain reduction was similar in the 
hydromorphone and tapentadol studies, but slightly poorer 
when compared to oxymorphone. Side effects were also 
similar for all groups, but tapentadol showed a better side 
effect profile versus oxycodone CR.
Open label trials
In a recent study by Friedmann et al, long-term safety and 
efficacy was assessed for oxycodone ER (Remoxy®) in 
patients with osteoarthritis of the knee and hip and low back 
pain.51 Throughout a 12-month period, 823 patients received 
one or more doses of oxycodone ER. One or more AEs were 
experienced by 678 patients (82%), with the most common 
side effects related to opioids (constipation, nausea, and 
somnolence), 173 patients (21%) discontinued treatment, 
133 patients (16%) decreased drug dose, and 80 patients 
(10%) interrupted taking the study drug because of AEs. 
A total of 55 patients experienced a serious AE, with five 
being considered related to the study drug. Mean pain inten-
sity scores decreased significantly from baseline (6.4 to 4.5; 
P , 0.001). At month twelve, quality of analgesia and global 
assessment of study drugs were rated positively (good, very 
good, or excellent) by 64% and 61% of patients, respectively. 
The authors concluded that oxycodone ER is safe, well toler-
ated, and a viable option for treating chronic pain related to 
osteoarthritis and low back pain.
Discussion
The American College of Rheumatology guidelines for the 
treatment of osteoarthritis recommend a variety of non-
pharmacologic interventions as the cornerstone of therapy. 
Pain management is most effective when combined with 
nonpharmacologic strategies. Patients with severe pain who 
do not respond to, or cannot tolerate, other analgesics may be 
considered for more potent opioid therapy.52 Chronic opioid 
therapy may be effective therapy for carefully selected and 
monitored patients with chronic noncancer pain.53
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Table 1 Studies assessing safety and efficacy of oxycodone controlled release in patients with osteoarthritis
Year Author Duration  
(months)
N Trial Other  
analgesics  
allowed
Dose Pain Quality of life indicators Discontinuations AEs
Placebo-controlled trials
2000 Roth et al42 12 133 R, DB Yes 10 mg every  
12 hours, 
20 mg every  
12 hours
Oxycodone CR group 
Daily mean pain intensity ↓ by $20%  
at weeks one and two (four-point scale)
Oxycodone CR group 
Significantly improved mood, sleep, enjoyment  
of life, walking ability, general activity,  
normal work, relationships with others
Oxycodone CR group 
IET = 17 (19.3%) 
AEs = 26 (29.5%) 
Placebo 
IET = 22 
AE = 2
AEs were typical opioid related. 
Top three AEs: constipation, nausea, somnolence
2005 Markenson  
et al43
3 170 R, DB Yes 10 mg every  
12 hours
Oxycodone versus placebo 
BPI pain intensity ↓ (5.1 ± 0.3 versus  
6.0 ± 0.3; P = 0.042) 
WOMAC scores for pain, stiffness, and 
physical function significantly ↓ at 30 and  
60 days. 38% versus 17.6% achieved 30% ↓ in 
pain. 20% versus 5.9% achieved 50% ↓ in pain
Oxycodone versus placebo 
BPI interference of pain scales for general activity,  
mood, walking ability, normal work, relations with  
people, sleep, and enjoyment of life significantly ↓
Oxycodone CR Group 
IET = 9 (16%) 
AEs = 20 (36%) 
Placebo 
IET = 34 (67%) 
AE = 2 (4%)
AEs were typical opioid related. 
Top three AEs: constipation, nausea, somnolence 
Oxymorphone versus oxycodone
2005 Matsumoto45 1 491 R, DB, A No Oxymorphone ER 
20 mg every  
12 hours, 
40 mg every  
12 hours 
Oxycodone CR 
20 mg every  
12 hours
API VAS ↓ significantly for oxymorphone  
groups at 3 weeks and 4 weeks, trended  
towards significance for oxycodone group 
WOMAC scores for pain, physical function,  
and stiffness significantly ↓	in oxymorphone  
groups versus placebo, no significant change  
in oxycodone versus placebo
Oxymorphone ER superior to placebo for Patient  
Global Assessment, oxycodone CR was not. 
Oxymorphone improved quality of life with  
physical and mental aspects, oxycodone improved  
only mental. Both improved sleep
Oxymorphone 
IET = 14 (5.8%) 
AEs = 103 (43%) 
Oxycodone 
IET = 13 (10.4%) 
AEs = 31 (24.8%) 
Placebo 
IET = 34 (27.4%) 
AEs = 6 (4.8%)
At least one AE was reported for 404 patients 
(83%) who received study medication: 
91% in the oxymorphone ER 40 mg group 
95% in the oxymorphone ER 20 mg group 
88% in the oxycodone CR 20 mg group 
57% in the placebo group. 
Frequent AEs typical of opioids
Hydromorphone versus oxycodone
2007 Hale et al46 1.5 138 R, OL Not  
described
Oxycodone 
Initial dose 10 mg  
every 12 hours ↑  
to 80 mg every  
12 hours 
Hydromorphone  
8 mg every 24 hours  
up to 64 mg every  
24 hours
Hydromorphone versus oxycodone 
Mean pain relief score of 2.3 versus 2.3  
(95% CI −0.30 to ∞) 
Mean time to the third day of moderate  
to complete pain relief was 6.2 versus 5.5 days  
(95% CI −0.31 to ∞). 
Mean (SD) changes in pain intensity was  
−0.6 (0.80) versus −0.4 (1.15) 
Mean changes in WOMAC pain scale was −2.1  
(1.96) versus −2.0 (2.03)
Patient/investigator global evaluations similar. 
Overall effectiveness of treatment rated as good,  
very good, or excellent by 67.2% (43/64) of patients  
in the OROS® hydromorphone group and 66.7%  
(40/60) of patients in the ER oxycodone group. 
Medical Outcomes Study Sleep Problems 
Index I indicated significantly less sleep disruption  
and daytime somnolence in hydromorphone  
versus oxycodone
Hydromorphone 
IET = 1/28 
AEs = 25/28 
Oxycodone 
IET = 3/27 
AEs = 22/27
Treatment-emergent AEs 
78.9% versus 79.1% 
AEs typical of opioid treatment
Tapentadol versus oxycodone
2010 Afilalo et al48 3 1030 R, DB, A,  
Placebo
No Tapentadol ER  
twice daily  
(100–250 mg) 
Oxycodone CR  
twice daily  
(20–50 mg)
Tapentadol ER 
Significantly ↓ average pain intensity  
versus placebo  
Mean difference of −0.7 (95% CI −1.04  
to −0.33) and throughout the maintenance  
period (−0.7 [−1.00 to −0.33]). 
Oxycodone CR 
Significantly ↓ average pain intensity from  
baseline throughout the maintenance period  
versus placebo mean difference −0.3  
[95% CI −0.67 to −0.00], but not at week twelve 
Tapentadol ER versus placebo 
Significantly ↑	percentage of patients achieving  
50% reduction in average pain intensity  
(32.0% [110/344] versus 24.3% [82/337];  
P = 0.027). 
Oxycodone CR versus placebo 
Percentage of patients achieving 50% reduction  
in average pain intensity (17.3% [59/342]  
versus 24.3% [82/337]; P = 0.023)
Tapentadol ER versus placebo 
Statistically significant improvement on the  
SF-36 “physical functioning,” “role-physical,”  
“bodily pain,” and “physical component summary”  
subscale scores. Significant differences in favor of placebo 
versus oxycodone CR for changes from baseline to end  
of treatment in the SF-36 “role-physical,” “vitality,” 
“social functioning,” “role-emotional,” “mental  
health,” and “mental component summary”  
subscale scores
Tapentadol 
IET = 15/163 
AEs = 61/163 
Oxycodone 
IET = 7/224 
AEs = 140/224
Treatment-emergent AEs 
Placebo: 61.1% (206/337) 
Tapentadol ER: 75.9% (261/344) 
Oxycodone CR: 87.4% (299/342) 
Frequent AEs typical of opioid treatment. 
Constipation and nausea/vomiting significantly ↓ in 
tapentadol. ER group versus oxycodone CR
(Continued)
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Table 1 Studies assessing safety and efficacy of oxycodone controlled release in patients with osteoarthritis
Year Author Duration  
(months)
N Trial Other  
analgesics  
allowed
Dose Pain Quality of life indicators Discontinuations AEs
Placebo-controlled trials
2000 Roth et al42 12 133 R, DB Yes 10 mg every  
12 hours, 
20 mg every  
12 hours
Oxycodone CR group 
Daily mean pain intensity ↓ by $20%  
at weeks one and two (four-point scale)
Oxycodone CR group 
Significantly improved mood, sleep, enjoyment  
of life, walking ability, general activity,  
normal work, relationships with others
Oxycodone CR group 
IET = 17 (19.3%) 
AEs = 26 (29.5%) 
Placebo 
IET = 22 
AE = 2
AEs were typical opioid related. 
Top three AEs: constipation, nausea, somnolence
2005 Markenson  
et al43
3 170 R, DB Yes 10 mg every  
12 hours
Oxycodone versus placebo 
BPI pain intensity ↓ (5.1 ± 0.3 versus  
6.0 ± 0.3; P = 0.042) 
WOMAC scores for pain, stiffness, and 
physical function significantly ↓ at 30 and  
60 days. 38% versus 17.6% achieved 30% ↓ in 
pain. 20% versus 5.9% achieved 50% ↓ in pain
Oxycodone versus placebo 
BPI interference of pain scales for general activity,  
mood, walking ability, normal work, relations with  
people, sleep, and enjoyment of life significantly ↓
Oxycodone CR Group 
IET = 9 (16%) 
AEs = 20 (36%) 
Placebo 
IET = 34 (67%) 
AE = 2 (4%)
AEs were typical opioid related. 
Top three AEs: constipation, nausea, somnolence 
Oxymorphone versus oxycodone
2005 Matsumoto45 1 491 R, DB, A No Oxymorphone ER 
20 mg every  
12 hours, 
40 mg every  
12 hours 
Oxycodone CR 
20 mg every  
12 hours
API VAS ↓ significantly for oxymorphone  
groups at 3 weeks and 4 weeks, trended  
towards significance for oxycodone group 
WOMAC scores for pain, physical function,  
and stiffness significantly ↓	in oxymorphone  
groups versus placebo, no significant change  
in oxycodone versus placebo
Oxymorphone ER superior to placebo for Patient  
Global Assessment, oxycodone CR was not. 
Oxymorphone improved quality of life with  
physical and mental aspects, oxycodone improved  
only mental. Both improved sleep
Oxymorphone 
IET = 14 (5.8%) 
AEs = 103 (43%) 
Oxycodone 
IET = 13 (10.4%) 
AEs = 31 (24.8%) 
Placebo 
IET = 34 (27.4%) 
AEs = 6 (4.8%)
At least one AE was reported for 404 patients 
(83%) who received study medication: 
91% in the oxymorphone ER 40 mg group 
95% in the oxymorphone ER 20 mg group 
88% in the oxycodone CR 20 mg group 
57% in the placebo group. 
Frequent AEs typical of opioids
Hydromorphone versus oxycodone
2007 Hale et al46 1.5 138 R, OL Not  
described
Oxycodone 
Initial dose 10 mg  
every 12 hours ↑  
to 80 mg every  
12 hours 
Hydromorphone  
8 mg every 24 hours  
up to 64 mg every  
24 hours
Hydromorphone versus oxycodone 
Mean pain relief score of 2.3 versus 2.3  
(95% CI −0.30 to ∞) 
Mean time to the third day of moderate  
to complete pain relief was 6.2 versus 5.5 days  
(95% CI −0.31 to ∞). 
Mean (SD) changes in pain intensity was  
−0.6 (0.80) versus −0.4 (1.15) 
Mean changes in WOMAC pain scale was −2.1  
(1.96) versus −2.0 (2.03)
Patient/investigator global evaluations similar. 
Overall effectiveness of treatment rated as good,  
very good, or excellent by 67.2% (43/64) of patients  
in the OROS® hydromorphone group and 66.7%  
(40/60) of patients in the ER oxycodone group. 
Medical Outcomes Study Sleep Problems 
Index I indicated significantly less sleep disruption  
and daytime somnolence in hydromorphone  
versus oxycodone
Hydromorphone 
IET = 1/28 
AEs = 25/28 
Oxycodone 
IET = 3/27 
AEs = 22/27
Treatment-emergent AEs 
78.9% versus 79.1% 
AEs typical of opioid treatment
Tapentadol versus oxycodone
2010 Afilalo et al48 3 1030 R, DB, A,  
Placebo
No Tapentadol ER  
twice daily  
(100–250 mg) 
Oxycodone CR  
twice daily  
(20–50 mg)
Tapentadol ER 
Significantly ↓ average pain intensity  
versus placebo  
Mean difference of −0.7 (95% CI −1.04  
to −0.33) and throughout the maintenance  
period (−0.7 [−1.00 to −0.33]). 
Oxycodone CR 
Significantly ↓ average pain intensity from  
baseline throughout the maintenance period  
versus placebo mean difference −0.3  
[95% CI −0.67 to −0.00], but not at week twelve 
Tapentadol ER versus placebo 
Significantly ↑	percentage of patients achieving  
50% reduction in average pain intensity  
(32.0% [110/344] versus 24.3% [82/337];  
P = 0.027). 
Oxycodone CR versus placebo 
Percentage of patients achieving 50% reduction  
in average pain intensity (17.3% [59/342]  
versus 24.3% [82/337]; P = 0.023)
Tapentadol ER versus placebo 
Statistically significant improvement on the  
SF-36 “physical functioning,” “role-physical,”  
“bodily pain,” and “physical component summary”  
subscale scores. Significant differences in favor of placebo 
versus oxycodone CR for changes from baseline to end  
of treatment in the SF-36 “role-physical,” “vitality,” 
“social functioning,” “role-emotional,” “mental  
health,” and “mental component summary”  
subscale scores
Tapentadol 
IET = 15/163 
AEs = 61/163 
Oxycodone 
IET = 7/224 
AEs = 140/224
Treatment-emergent AEs 
Placebo: 61.1% (206/337) 
Tapentadol ER: 75.9% (261/344) 
Oxycodone CR: 87.4% (299/342) 
Frequent AEs typical of opioid treatment. 
Constipation and nausea/vomiting significantly ↓ in 
tapentadol. ER group versus oxycodone CR
(Continued)
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Table 1 (Continued)
Year Author Duration  
(months)
N Trial Other  
analgesics  
allowed
Dose Pain Quality of life indicators Discontinuations AEs
2010 Wild et al49 12 1117 R, OL, A No Tapentadol ER 
twice daily  
(100–250 mg) 
Oxycodone CR  
twice daily  
(20–50 mg)
Tapentadol versus oxycodone 
Baseline mean (SE) pain intensity scores 7.6  
(0.05) versus 7.6 (0.11) 
At endpoint, mean pain intensity (SE) ↓ to 4.4  
(0.09) versus 4.5 (0.17)
Tapentadol versus oxycodone 
Global assessment of excellent, very good, or good  
were reported by patients (75.1% versus 72.3%)  
and investigators (77.3% versus 72.3%)
Tapentadol 
IET = 72 (8.1%) 
AEs = 203 (22.7%) 
Oxycodone 
IET = 7 (3.1%) 
AEs = 82 (36.8%)
85.7% (766/894) versus 90.6% (202/223) 
experienced at least one treatment-emergent AE. 
Frequent AEs typical of opioid treatment 
Incidences (tapentadol versus oxycodone) 
Constipation: 
22.6% versus 38.6% 
Nausea: 
18.1% versus 33.2% 
Vomiting: 
7.0% versus 13.5% 
Pruritus: 
5.4% versus 10.3% 
Dizziness: 
14.8% versus 19.3%
Open label trials
2011 Friedman51 12 823 OL Yes 5–80 mg every  
12 hours
Pain intensity scores significantly ↓ compared  
to baseline (P # 0.001) 
Mean (SD) change in pain intensity scores  
at month six was −2.0 (2.6) and at month  
twelve was −2.1 (2.7; P # 0.001)
Quality of analgesia was rated as good, very good, 
or excellent at months six and twelve by  
61% and 64% of patients. 
Study drug was rated as good, very good,  
or excellent by 60% and 61% of patients
IET = 15/443 
AEs = 173/443
678/823 (82%) experienced at least one AE 
Frequent AEs typical of opioid treatment
Abbreviations: A, active controlled; AE, adverse event; API, Arthritis Pain Inventory; BPI, Brief Pain Inventory; CI, confidence interval; DB, double-blind; IET, ineffective 
treatment; OL, open label; R, randomized; SD, standard deviation; SE, standard error; VAS, Visual Analog Scale; WOMAC, Western Ontario and McMaster University 
Osteoarthritis Index.
Caring for patients struggling with moderate to severe 
chronic osteoarthritis pain requires the clinician to carefully 
weigh the benefits and disadvantages of long-term opioid therapy 
and to select the appropriate opioid product. Pharmacokinetic 
conclusions that intravenous oxycodone CR has a significantly 
longer half-life in older versus younger patients (3.8 hours in 
25 year olds and 4.6 hours in 85 year olds) is not surprising 
but concerning, although one cannot draw conclusions about 
the use of oral oxycodone from this study.   Age-dependent 
pharmacokinetic differences have been observed and mean 
that oxycodone, and indeed other opioids, must be used pru-
dently and under close clinical supervision in the elderly, that 
is, the population most likely to suffer from osteoarthritis pain. 
Oxycodone CR clearly offered significant pain relief when 
compared to placebo, but that relief was associated with the 
typical side effects of opioid agents: constipation, somnolence, 
pruritus, nausea, nervousness, headache, and insomnia. Such 
side effects can often be successfully managed, but it is impor-
tant to recognize that in these studies, some patients experienced 
possibly drug-related serious AEs.
Several of these studies showed durable analgesia with 
oxycodone CR and patients reported being satisfied with the 
treatment, which reportedly did not adversely impact their 
ability to carry out the activities of everyday living. Quality 
of life improvements along with better sleep and mood were 
reported with oxycodone CR. These are important findings, 
in that patients with moderate to severe osteoarthritis pain 
require long-term, even lifelong, pain management.
When oxycodone CR was compared to specific other 
analgesics (oxycodone ER, oxymorphone, hydromorphone, 
and tapentadol), oxycodone CR was not found to be sig-
nificantly safer or more effective. Oxymorphone offered 
greater pain relief; tapentadol patients had fewer side effects. 
However, the current review mixed studies with different 
objectives and designs. It is reasonable to conclude that 
oxycodone CR offered similar, but not superior, safety and 
efficacy compared to the aforementioned agents.
The literature reviewed supports the fact that oxycodone 
CR is safe and effective and significantly reduces moderate 
to severe chronic pain in osteoarthritis patients with the 
expected side effects associated with other opioid agents. 
Comparative studies indicate that it is similar to other 
products, which means that clinicians should consider the 
individual needs of each patient when selecting a long-term 
opioid to manage moderate to severe chronic pain associated 
with osteoarthritis. Physicians need to consider the risks 
and benefits of long-acting opioids in their osteoarthritis 
patients. Risk-benefit considerations include, but are not 
limited to, variability of patient response,54 potential drug–
drug interactions,55 potential side effects, opioid rotation, and 
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Table 1 (Continued)
Year Author Duration  
(months)
N Trial Other  
analgesics  
allowed
Dose Pain Quality of life indicators Discontinuations AEs
2010 Wild et al49 12 1117 R, OL, A No Tapentadol ER 
twice daily  
(100–250 mg) 
Oxycodone CR  
twice daily  
(20–50 mg)
Tapentadol versus oxycodone 
Baseline mean (SE) pain intensity scores 7.6  
(0.05) versus 7.6 (0.11) 
At endpoint, mean pain intensity (SE) ↓ to 4.4  
(0.09) versus 4.5 (0.17)
Tapentadol versus oxycodone 
Global assessment of excellent, very good, or good  
were reported by patients (75.1% versus 72.3%)  
and investigators (77.3% versus 72.3%)
Tapentadol 
IET = 72 (8.1%) 
AEs = 203 (22.7%) 
Oxycodone 
IET = 7 (3.1%) 
AEs = 82 (36.8%)
85.7% (766/894) versus 90.6% (202/223) 
experienced at least one treatment-emergent AE. 
Frequent AEs typical of opioid treatment 
Incidences (tapentadol versus oxycodone) 
Constipation: 
22.6% versus 38.6% 
Nausea: 
18.1% versus 33.2% 
Vomiting: 
7.0% versus 13.5% 
Pruritus: 
5.4% versus 10.3% 
Dizziness: 
14.8% versus 19.3%
Open label trials
2011 Friedman51 12 823 OL Yes 5–80 mg every  
12 hours
Pain intensity scores significantly ↓ compared  
to baseline (P # 0.001) 
Mean (SD) change in pain intensity scores  
at month six was −2.0 (2.6) and at month  
twelve was −2.1 (2.7; P # 0.001)
Quality of analgesia was rated as good, very good, 
or excellent at months six and twelve by  
61% and 64% of patients. 
Study drug was rated as good, very good,  
or excellent by 60% and 61% of patients
IET = 15/443 
AEs = 173/443
678/823 (82%) experienced at least one AE 
Frequent AEs typical of opioid treatment
Abbreviations: A, active controlled; AE, adverse event; API, Arthritis Pain Inventory; BPI, Brief Pain Inventory; CI, confidence interval; DB, double-blind; IET, ineffective 
treatment; OL, open label; R, randomized; SD, standard deviation; SE, standard error; VAS, Visual Analog Scale; WOMAC, Western Ontario and McMaster University 
Osteoarthritis Index.
possibility of abuse, misuse, or addiction.53 The following 
points should be considered when identifying the appropri-
ate patient for oxycodone CR therapy: (a) have they tried 
nonpharmacologic interventions?; (b) have they failed to 
respond or cannot tolerate nonopioid analgesics?; and (c) are 
immediate release opioids dosed every 4–6 hours around-
the-clock being considered or might they benefit from every 
12 hours dosing?56 If the patient is an appropriate candidate 
for long-acting oxycodone therapy, then the next step is to 
assess his or her pain, the historical level of pain, and any 
history of abuse. Therapy should be targeted at achieving 
optimal analgesia at the lowest effective dose.
Limitations
This is a literature review and not a meta-analysis. The litera-
ture search relied on keywords being present in the article title 
and no attempt was made to assess the quality of the study. 
This might result in overemphasizing lower-quality studies 
or underemphasizing higher-quality ones. The eleven studies 
identified included placebo-controlled, comparative, safety, 
and pharmacokinetic studies which have, by definition, dif-
ferent objectives. Thus, there is a distinct heterogeneity of 
results with no attempt made to weight studies by goals or 
design. Further, no attempts were made to stratify the find-
ings based on studies involving knee osteoarthritis versus hip 
osteoarthritis or other types of osteoarthritis. As a result, the 
paper should be viewed as offering a high-level overview of 
oxycodone CR products in the treatment of osteoarthritis pain 
rather than providing specific clinical insights.
Conclusion
Clinical studies have demonstrated reasonable efficacy, safety, 
and tolerability of oxycodone CR when used to manage mod-
erate to severe chronic osteoarthritis pain. The most common 
AEs are gastrointestinal and central nervous system related. 
These side effects might be more pronounced in elderly and 
debilitated patients. All patients need to be regularly assessed 
for the potential of abuse, misuse, and addiction, as well as 
the need for continued opioid therapy. Finally, it is important 
to incorporate a multimodal pain management regimen that 
includes nonpharmacologic and pharmacologic therapies 
when treating chronic osteoarthritis-related pain.
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